Get the Stockscreener App
4.82
0.42%
-0.03
Nyxoah Sa stock is traded at $4.82, with a volume of 28,985.
It is down -0.42% in the last 24 hours and up +6.71% over the past month.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
See More
Previous Close:
$4.79
Open:
$4.82
24h Volume:
28,985
Relative Volume:
0.70
Market Cap:
$207.39M
Revenue:
$4.71M
Net Income/Loss:
$-46.77M
P/E Ratio:
-2.8704
EPS:
-1.6792
Net Cash Flow:
$-60.34M
1W Performance:
+0.85%
1M Performance:
+6.71%
6M Performance:
-37.07%
1Y Performance:
-55.96%
1-Day Range:
$4.70
$4.92
1-Week Range:
$4.66
$5.00
52-Week Range:
$4.345
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
Name
Nyxoah Sa
Sector
Industry
Phone
-
Address
-
Compare NYXH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
4.82 | 206.10M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
525.05 | 187.46B | 10.06B | 2.88B | 2.27B | 7.8807 |
|
BDX
Becton Dickinson Co
|
204.63 | 57.96B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.84 | 39.68B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
45.40 | 37.32B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
257.39 | 37.29B | 5.26B | 1.44B | 1.76B | 9.7713 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-21-22 | Initiated | Oppenheimer | Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Dec-21-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-28-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Nyxoah Sa Stock (NYXH) Latest News
Can Nyxoah SA sustain its profitabilityJuly 2025 Big Picture & AI Powered Buy and Sell Recommendations - mfd.ru
Volume Report: Can Nyxoah SA ride the EV waveQuarterly Portfolio Review & Weekly High Return Forecasts - baoquankhu1.vn
Nyxoah Expands Belgian Manufacturing Capacity to Support Global Growth - Sleep Review
Nyxoah says co invests expanding its Belgian manufacturing capacity - marketscreener.com
Sleep apnea-focused Nyxoah to add Belgian plant as US demand grows - Stock Titan
Does Nyxoah SA have pricing power2025 Risk Factors & Growth Focused Stock Reports - bollywoodhelpline.com
Aug Sectors: Is Flanigans Enterprises Inc stock a falling knife or bargain buy2025 Fundamental Recap & Intraday High Probability Alerts - baoquankhu1.vn
(NYXH) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
NYXH: Rapid U.S. launch and strong clinical results position Genio for significant market growth - TradingView
NYXH: Genio's innovative sleep apnea device drives rapid U.S. adoption and strong early sales - TradingView — Track All Markets
Oppenheimer Maintains Nyxoah SA(NYXH.US) With Buy Rating, Maintains Target Price $13 - 富途牛牛
Nyxoah’s First Full U.S. Sales Quarter Fuels Triple-Digit Revenue Growth in 2025 - TipRanks
Nyxoah (NASDAQ: NYXH) reports preliminary 2025 results and Q1 2026 view - Stock Titan
Stifel reiterates Buy rating on Nyxoah stock, maintains $12 price target By Investing.com - Investing.com South Africa
Stifel Maintains Nyxoah SA(NYXH.US) With Buy Rating, Maintains Target Price $12 - 富途资讯
Stifel reiterates Buy rating on Nyxoah stock, maintains $12 price target - Investing.com Australia
Is Nyxoah SA stock a safe investment in uncertain markets2025 Growth vs Value & Verified Swing Trading Watchlist - Bộ Nội Vụ
Belgium-based Nyxoah’s net revenue expected to increase 348% in Q4 2025 - Medical Buyer
Nyxoah Shares Surge On Strong Q4 Preliminary Revenue - Nasdaq
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 - The Manila Times
News - FinancialContent
Nyxoah SA's (EBR:NYXH) market cap rose €19m last week; retail investors who hold 44% profited and so did insiders - simplywall.st
Publication relating to transparency notification - GlobeNewswire
Aug Opening: Is Nyxoah SA stock a contrarian buyJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - Bộ Nội Vụ
Is Nyxoah SA stock a good choice for value investorsSeasonal Picks & what to check before ordering - Улправда
Is Nyxoah SA stock a contrarian buyMarket Risk Summary & Free Fast Gain Swing Trade Alerts - Улправда
How Nyxoah SA (5YI) stock benefits from digital adoptionPortfolio Growth Summary & Free Safe Entry Trade Signal Reports - ulpravda.ru
Aug Intraday: Is Nyxoah SA stock a good choice for value investors2025 Technical Overview & Community Consensus Trade Alerts - Улправда
Why Nyxoah SA stock is recommended by analysts2025 Pullback Review & Safe Entry Momentum Stock Tips - ulpravda.ru
Nyxoah SA (NYXH) Stock Analysis: Exploring a Potential 125.84% Upside in the Healthcare Sector - DirectorsTalk Interviews
Nyxoah receives Medicare reimbursement increases for Genio - MSN
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
PRN_FinancialWrapper | PR NewswireNyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Contrasting Azenta (NASDAQ:AZTA) and Nyxoah (NASDAQ:NYXH) - Defense World
Baird Maintains Nyxoah SA(NYXH.US) With Hold Rating, Cuts Target Price to $5.87 - 富途牛牛
Nyxoah to Participate in Upcoming Investor Conferences - Macau Business
Nyxoah SA (NYXH) Stock Analysis: Exploring a 145.53% Potential Upside in the Medical Tech Sector - DirectorsTalk Interviews
Nyxoah announces commercial launch of Genio system in the Netherlands - MSN
Nyxoah launches Genio therapy in Netherlands and closes first €22.5 million tranche of convertible notes - MSN
Nyxoah price target lowered to EUR 5 from EUR 7 at Baird - MSN
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference - Macau Business
Nyxoah Announces Issuance of First Tranche of Convertible Bonds - The Manila Times
Is Nyxoah SA stock positioned for digital transformationQuarterly Trade Review & Consistent Return Investment Signals - Улправда
Nyxoah Launches Genio Therapy in Netherlands and Closes First €22.5 Million Tranche of Convertible Notes - TipRanks
Earnings Recap: Is Nyxoah SA stock a good choice for value investorsJuly 2025 Highlights & Target Return Focused Picks - Bộ Nội Vụ
Can Nyxoah SA stock deliver strong Q4 earningsQuarterly Growth Report & Smart Swing Trading Alerts - DonanımHaber
Is Nyxoah SA (5YI) stock undervalued historicallyJuly 2025 Sentiment & Daily Profit Maximizing Tips - DonanımHaber
Sleep apnea device maker Nyxoah secures €22.5M to extend cash runway - Stock Titan
How Nyxoah SA stock performs in high volatility markets2025 Historical Comparison & Expert Curated Trade Setups - ulpravda.ru
Nyxoah Launches New OSA Therapy | Patient-Centric Breakthrough - Precedence Research
Nyxoah Launches Genio Neurostimulator System in the Netherlands - marketscreener.com
Nyxoah Sa Stock (NYXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):